Key Takeaways
- • Healthcare private equity achieved a record $191 billion in disclosed deal value during 2025, surpassing the previous peak of 2021, with 445 announced buyouts marking the second-highest annual volume on record.
- • Megadeals drove performance, with deal counts growing across all size brackets; large transactions exceeding $1 billion significantly contributed to the record valuation.
- • Exit activity rebounded sharply, with exit value reaching $156 billion in 2025 (up from $54 billion in 2024), driven by more than 40 exits exceeding $1 billion compared to only 16 in the prior year.
- • Provider, biopharma, and healthcare IT segments led market activity, while medtech demonstrated outsized growth momentum since 2020.
- • Abundant dry powder and a growing cohort of sponsor-owned assets approaching fund maturity signal sustained tailwinds for continued dealmaking activity in 2026.
Summary
Healthcare private equity delivered exceptional performance in 2025, with global deal activity reaching an estimated $191 billion in disclosed value—a new record that eclipsed the previous high watermark established in 2021. This performance reflected both robust deal volume and the continued dominance of large transactions in shaping overall market value. According to Bain & Company's analysis, investors announced approximately 445 buyouts during the year, representing the second-highest annual transaction count on record, trailing only the 2021 peak.
The surge in aggregate deal value was substantially driven by an uptick in transactions exceeding $1 billion, though deal counts expanded across all size categories. This diversified growth pattern indicates broad-based strength in the healthcare PE market rather than concentration in a narrow band of mega-transactions. The strength reflected underlying market conditions characterized by abundant capital available for deployment and an increasingly mature portfolio of sponsor-backed assets approaching the natural conclusion of fund investment periods.
Exit activity emerged as a particular bright spot, with sponsor-to-sponsor transactions rebounding from post-pandemic lows and public market opportunities remaining active. Exit value reached an anticipated $156 billion for 2025, the second-highest on record, driven substantially by large exits. The contrast with 2024 proves instructive: only 16 exits exceeded $1 billion in disclosed value that year, whereas more than 40 such exits have cleared this threshold in 2025—a more than 150% increase in mega-exit frequency.
Provider organizations and biopharma companies represented the largest market segments, with healthcare IT activity providing particular momentum within the provider category. Medical devices and medtech subsectors have demonstrated outsized growth rates since 2020, indicating a structural shift in investor focus toward this vertical. The combination of substantial dry powder available across PE funds and a growing pipeline of mature sponsor-held assets reaching liquidity windows suggests sustained tailwinds for continued market activity through 2026.
The surge in aggregate deal value was substantially driven by an uptick in transactions exceeding $1 billion, though deal counts expanded across all size categories. This diversified growth pattern indicates broad-based strength in the healthcare PE market rather than concentration in a narrow band of mega-transactions. The strength reflected underlying market conditions characterized by abundant capital available for deployment and an increasingly mature portfolio of sponsor-backed assets approaching the natural conclusion of fund investment periods.
Exit activity emerged as a particular bright spot, with sponsor-to-sponsor transactions rebounding from post-pandemic lows and public market opportunities remaining active. Exit value reached an anticipated $156 billion for 2025, the second-highest on record, driven substantially by large exits. The contrast with 2024 proves instructive: only 16 exits exceeded $1 billion in disclosed value that year, whereas more than 40 such exits have cleared this threshold in 2025—a more than 150% increase in mega-exit frequency.
Provider organizations and biopharma companies represented the largest market segments, with healthcare IT activity providing particular momentum within the provider category. Medical devices and medtech subsectors have demonstrated outsized growth rates since 2020, indicating a structural shift in investor focus toward this vertical. The combination of substantial dry powder available across PE funds and a growing pipeline of mature sponsor-held assets reaching liquidity windows suggests sustained tailwinds for continued market activity through 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.